{"schema_version":"1.0","type":"article","title":"18分鐘驗血，就能揪出阿茲海默症？禮來、羅氏真正搶的是「患者入口」","url":"https://drugnews.com.tw/articles/2026-09-05-elecsys-ptau217-alzheimers-blood-test.html","markdown_url":"https://drugnews.com.tw/articles/2026-09-05-elecsys-ptau217-alzheimers-blood-test.md","lang":"zh-Hant","date":"2026-09-05","publish_at":"2026-09-05T08:00:00+08:00","updated_at":"2026-09-05","category":"商業分析系列","topic":"商業分析系列","tags":["阿茲海默症","pTau217","血液檢測","診斷","羅氏","禮來"],"summary":"Elecsys pTau217協助評估Aβ病理可能性，18分鐘不是確診承諾。本文拆解羅氏、禮來及檢驗通路的角色，以及患者評估、採用與支付的限制。","key_points":[],"facts":[],"sections":[],"references":[],"images":[{"alt":"封面：18 分鐘與患者入口","url":"https://drugnews.com.tw/assets/articles/elecsys-ptau217-alzheimers-blood-test/01_%E5%B0%81%E9%9D%A2_18%E5%88%86%E9%90%98%E9%A9%97%E8%A1%80%E4%B8%8D%E6%98%AF%E7%A2%BA%E8%A8%BA.png"},{"alt":"機制：Aβ 病理如何連到血漿 pTau217","url":"https://drugnews.com.tw/assets/articles/elecsys-ptau217-alzheimers-blood-test/02_pTau217%E7%97%85%E7%90%86%E9%80%A3%E5%8B%95%E6%A9%9F%E5%88%B6.png"},{"alt":"診斷分流：誰能驗、結果怎麼走","url":"https://drugnews.com.tw/assets/articles/elecsys-ptau217-alzheimers-blood-test/03_clinical_pathway_zh_r2.png"},{"alt":"患者入口與商業鏈＋三道閘門","url":"https://drugnews.com.tw/assets/articles/elecsys-ptau217-alzheimers-blood-test/04_%E6%82%A3%E8%80%85%E5%85%A5%E5%8F%A3%E8%88%87%E5%95%86%E6%A5%AD%E9%8F%88.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/elecsys-ptau217-alzheimers-blood-test/00_cover_no_text_r1.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-09-05）。18分鐘驗血，就能揪出阿茲海默症？禮來、羅氏真正搶的是「患者入口」。https://drugnews.com.tw/articles/2026-09-05-elecsys-ptau217-alzheimers-blood-test.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}